SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
To donate by check, phone, or other method, see our More Ways to Give page.
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
The NYT is reporting that PhRMA will spend $150 million in advertising to support the White House health care plan in August:
The drug industry has already
contributed millions of dollars to advertising campaigns for the health
care overhaul through the advocacy groups like Healthy Economies Now
and Families USA. It has spent about $1 million on similar
advertisements under its own name.All of the commercials closely echo common Democratic themes about
medical care for all, consumer protection and "health insurance
reform." Some supporters of the overhaul have hired public affairs and
advertising firms with close ties to the White House and Senate
Democrats, including GMMB, which worked on the Obama campaign, and
AKPD, which previously included David Axelrod, who is now the
president's top political adviser.
In a statement released by the President on June 20:
I am pleased to announce that an
agreement has been reached between Senator Max Baucus and the nation's
pharmaceutical companies that will bring down health care costs and
reduce the price of prescription drugs for millions of America's
seniors. As part of the health reform legislation that I expect
Congress to enact this year, pharmaceutical companies will extend
discounts on prescription drugs to millions of seniors who currently
are subjected to crushing out-of-pocket expenses when the yearly
amounts they pay for medication fall within the doughnut hole any
payments by seniors not covered by Medicare that fall between $2700 and
$6153.75 per year.
Former Blue Dog Billy Tauzin, who now heads PhRMA, told the New York
Times it was a "rock solid deal." Jim "Stickboy" Messina (Obama's "Josh
Lyman") "confirmed Mr. Tauzin's account of the deal in an e-mail
message" to the NYT.
McJoan asked
the other day if Baucus is writing the White House's health care bill.
I don't think there is any question that he is, that Tauzin knows he
is, and that the idea that he's "holding up" the White House is not
grounded in reality. And that the deal cuts the legs out from
underneath Jeff Merkeley, who was trying to negotiate for $63 billion in rebates for drugs provided under Medicare.
The only question is how much the Democrats got in exchange for gutting the government's ability to control health care costs.
During the campaign, this was Obama's position:
Obama will allow Americans to buy their
medicines from other developed countries if the drugs are safe and
prices are lower outside the U.S. Obama will also repeal the ban that
prevents the government from negotiating with drug companies, which could result in savings as high as $30 billion.
It no longer appears on the health care page at mybarackobama.com.
But, let's do the math. In ten years, $30 billion a year would
mean $300 billion in savings. The deal cut by the White House is for
$80 billion in savings. So the pharmaceutical industry gets to keep
$220 billion for the low low price of $150 million in August to pass
health care reform so Rahm Emanual won't be 13-1.
A hundred fifty million for two hundred twenty billion in savings: an excellent return on investment by anyone's standards.
Common Dreams is powered by optimists who believe in the power of informed and engaged citizens to ignite and enact change to make the world a better place. We're hundreds of thousands strong, but every single supporter makes the difference. Your contribution supports this bold media model—free, independent, and dedicated to reporting the facts every day. Stand with us in the fight for economic equality, social justice, human rights, and a more sustainable future. As a people-powered nonprofit news outlet, we cover the issues the corporate media never will. |
The NYT is reporting that PhRMA will spend $150 million in advertising to support the White House health care plan in August:
The drug industry has already
contributed millions of dollars to advertising campaigns for the health
care overhaul through the advocacy groups like Healthy Economies Now
and Families USA. It has spent about $1 million on similar
advertisements under its own name.All of the commercials closely echo common Democratic themes about
medical care for all, consumer protection and "health insurance
reform." Some supporters of the overhaul have hired public affairs and
advertising firms with close ties to the White House and Senate
Democrats, including GMMB, which worked on the Obama campaign, and
AKPD, which previously included David Axelrod, who is now the
president's top political adviser.
In a statement released by the President on June 20:
I am pleased to announce that an
agreement has been reached between Senator Max Baucus and the nation's
pharmaceutical companies that will bring down health care costs and
reduce the price of prescription drugs for millions of America's
seniors. As part of the health reform legislation that I expect
Congress to enact this year, pharmaceutical companies will extend
discounts on prescription drugs to millions of seniors who currently
are subjected to crushing out-of-pocket expenses when the yearly
amounts they pay for medication fall within the doughnut hole any
payments by seniors not covered by Medicare that fall between $2700 and
$6153.75 per year.
Former Blue Dog Billy Tauzin, who now heads PhRMA, told the New York
Times it was a "rock solid deal." Jim "Stickboy" Messina (Obama's "Josh
Lyman") "confirmed Mr. Tauzin's account of the deal in an e-mail
message" to the NYT.
McJoan asked
the other day if Baucus is writing the White House's health care bill.
I don't think there is any question that he is, that Tauzin knows he
is, and that the idea that he's "holding up" the White House is not
grounded in reality. And that the deal cuts the legs out from
underneath Jeff Merkeley, who was trying to negotiate for $63 billion in rebates for drugs provided under Medicare.
The only question is how much the Democrats got in exchange for gutting the government's ability to control health care costs.
During the campaign, this was Obama's position:
Obama will allow Americans to buy their
medicines from other developed countries if the drugs are safe and
prices are lower outside the U.S. Obama will also repeal the ban that
prevents the government from negotiating with drug companies, which could result in savings as high as $30 billion.
It no longer appears on the health care page at mybarackobama.com.
But, let's do the math. In ten years, $30 billion a year would
mean $300 billion in savings. The deal cut by the White House is for
$80 billion in savings. So the pharmaceutical industry gets to keep
$220 billion for the low low price of $150 million in August to pass
health care reform so Rahm Emanual won't be 13-1.
A hundred fifty million for two hundred twenty billion in savings: an excellent return on investment by anyone's standards.
The NYT is reporting that PhRMA will spend $150 million in advertising to support the White House health care plan in August:
The drug industry has already
contributed millions of dollars to advertising campaigns for the health
care overhaul through the advocacy groups like Healthy Economies Now
and Families USA. It has spent about $1 million on similar
advertisements under its own name.All of the commercials closely echo common Democratic themes about
medical care for all, consumer protection and "health insurance
reform." Some supporters of the overhaul have hired public affairs and
advertising firms with close ties to the White House and Senate
Democrats, including GMMB, which worked on the Obama campaign, and
AKPD, which previously included David Axelrod, who is now the
president's top political adviser.
In a statement released by the President on June 20:
I am pleased to announce that an
agreement has been reached between Senator Max Baucus and the nation's
pharmaceutical companies that will bring down health care costs and
reduce the price of prescription drugs for millions of America's
seniors. As part of the health reform legislation that I expect
Congress to enact this year, pharmaceutical companies will extend
discounts on prescription drugs to millions of seniors who currently
are subjected to crushing out-of-pocket expenses when the yearly
amounts they pay for medication fall within the doughnut hole any
payments by seniors not covered by Medicare that fall between $2700 and
$6153.75 per year.
Former Blue Dog Billy Tauzin, who now heads PhRMA, told the New York
Times it was a "rock solid deal." Jim "Stickboy" Messina (Obama's "Josh
Lyman") "confirmed Mr. Tauzin's account of the deal in an e-mail
message" to the NYT.
McJoan asked
the other day if Baucus is writing the White House's health care bill.
I don't think there is any question that he is, that Tauzin knows he
is, and that the idea that he's "holding up" the White House is not
grounded in reality. And that the deal cuts the legs out from
underneath Jeff Merkeley, who was trying to negotiate for $63 billion in rebates for drugs provided under Medicare.
The only question is how much the Democrats got in exchange for gutting the government's ability to control health care costs.
During the campaign, this was Obama's position:
Obama will allow Americans to buy their
medicines from other developed countries if the drugs are safe and
prices are lower outside the U.S. Obama will also repeal the ban that
prevents the government from negotiating with drug companies, which could result in savings as high as $30 billion.
It no longer appears on the health care page at mybarackobama.com.
But, let's do the math. In ten years, $30 billion a year would
mean $300 billion in savings. The deal cut by the White House is for
$80 billion in savings. So the pharmaceutical industry gets to keep
$220 billion for the low low price of $150 million in August to pass
health care reform so Rahm Emanual won't be 13-1.
A hundred fifty million for two hundred twenty billion in savings: an excellent return on investment by anyone's standards.